NeurologyWire

Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue

From NeurologyWire

Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transactio...

Read full article

Friday, November 21, 2014

Show last days of articles

Study Identifies Early Warning Signs of Stroke Risk in Black...

From NeurologyWire

Researchers in The University of Texas at Austins College of Education have found that a blood flow impairment in blacks that puts them at higher risk...Full story

Thursday, November 20, 2014

Treatment Offers Promise for Spinal Cord Injury Patients to ...

From NeurologyWire

Case Western Reserve researcher presents findings that could free patients from ventilators, even years after injury.Case Western Reserve researchers ...Full story

FDA Approves Another Opioid With Abuse-Deterrent Properties

From NeurologyWire

FDA today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, aroun...Full story

Promising Phase II Results Seen in Parkinson's Drug

From NeurologyWire

Cynapsus Therapeutics has released positive top-line results from its CTH-105 Phase 2 clinical trial of APL-130277 for the management of OFF motor sym...Full story

Wednesday, November 19, 2014

Laws Spreading That Allow Terminal Patients Access To Experi...

From NeurologyWire

By Michelle Andrews for KHNEarlier this month, Arizona voters approved a referendum that allows terminally ill patients to receive experimental drugs ...Full story

Researchers Prevent Memory Problems Caused by Sleep Deprivat...

From NeurologyWire

In a new study, published in the Journal of Neuroscience, a team led by scientists from the University of Pennsylvania found that a particular set of ...Full story

Study Shows In Vivo Reversal Of Huntington's Disease Signs A...

From NeurologyWire

Positive preclinical data from a study on the novel ZFP Therapeutic will be presented Wednesday at 3:45 at the 2014 Annual Meeting of the Society for ...Full story

Brain Receptor Cell Could Be New Target for Alzheimer's

From NeurologyWire

Blocking a key receptor in brain cells that is used by oxygen free radicals could play a major role in neutralizing the biological consequences of Alz...Full story

Tuesday, November 18, 2014

Researchers Explore Link Between Memory Deficit and Misfirin...

From NeurologyWire

By disrupting Siberian hamsters circadian rhythms, Stanford scientists have identified a part of the brain that, when misfiring, inhibits memory. The ...Full story

Clinical Tests Help Differentiate Parkinson's from Atypical ...

From NeurologyWire

Two simple tests conducted during the neurological exam can help clinicians differentiate between early-stage Parkinson's disease (PD) and atypical pa...Full story

Monday, November 17, 2014

A New Genetic Cause for a Progressive Form of Epilepsy Ident...

From NeurologyWire

A study led by researchers at University of Helsinki, Finland and Universities of Melbourne and South Australia has identified a new gene for a progre...Full story

Several neuro drugs see labeling change

From NeurologyWire

Labeling changes were made to 37 products in October by FDA, and several of them had a neurological bend in their use.StrokeAldactazide (spironolacton...Full story

Valeant Comments On Allergan Announcement

From NeurologyWire

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE:...Full story

Actavis to Acquire Allergan to Create Top 10 Global Growth P...

From NeurologyWire

Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acq...Full story

MS drug Lemtrada approved by FDA

From NeurologyWire

FDA has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, ...Full story